SAF
CLPT icon

Smith Anglin Financial’s ClearPoint Neuro CLPT Stock Holding History

Smith Anglin Financial’s Portfolio CLPT Stock Details CLPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-20,000
Closed -$207K – 157
2022
Q3 		$207K Buy
+20,000
New +$264K 0.04% 132

Other funds holding CLPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CWM
Cahill Wealth Management Portage, Michigan $196M AUM 8.5% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Smith Anglin Financial's CLPT Position: Q4 2022 in Review

Smith Anglin Financial sold out of ClearPoint Neuro (CLPT) in Q4 2022, closing a stake of 20,000 shares — an estimated $207K sold.

Smith Anglin Financial first reported a position in CLPT in Q3 2022 and held it in 1 quarter. The position peaked at $207K in Q3 2022. 62 funds tracked by Wall St. Rank hold CLPT as of Q4 2022.

  • Smith Anglin Financial reported no remaining ClearPoint Neuro position as of Q4 2022 after selling out during the quarter.
  • Smith Anglin Financial sold 20,000 ClearPoint Neuro shares in Q4 2022, an estimated $207K.
  • Smith Anglin Financial first reported a position in ClearPoint Neuro in Q3 2022 and held it in 1 quarter.
  • Smith Anglin Financial's ClearPoint Neuro position peaked at $207K in Q3 2022.
  • 62 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q4 2022.

Based on Smith Anglin Financial's 13F filing for Q4 2022, filed 14 Feb 2023.